查看原文
其他

外媒:世卫组织批准国药新冠疫苗对发展中国家至关重要

CGTN 2021-05-12

全球疫苗免疫联盟(GAVI)的发言人5月11日表示,GAVI正在与包括中国国药在内的疫苗厂商洽谈,以扩大疫苗供应和发放。



世界卫生组织5月7日批准中国国药新冠疫苗用于紧急使用,为推动中国在全球新冠疫苗接种方面发挥了重要作用。 


The Gavi Vaccine Alliance is in talks with COVID-19 vaccine manufacturers including China’s state-owned Sinopharm to expand the COVAX pipeline and secure doses for distribution, a Gavi spokeswoman said Monday.


Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing’s push for a bigger role in inoculating the world.


据英国《卫报》5月7日报道,多名专家表示,世卫组织批准中国国药新冠疫苗用于紧急使用对于发展中国家尤其重要。


日内瓦高级国际关系及发展学院“全球健康项目”负责人Suerie Moon表示,“如果获批,这些疫苗将使‘新冠肺炎疫苗实施计划’疫苗供应量大幅增长。”

Experts said today’s decision by the world’s top public health authority could be a gamechanger, especially for developing countries.


“If there is a green light, these vaccines could boost the thin stream of supplies that has been channelled through Covax to date,” Suerie Moon, co-director of the Global Health Programme at Geneva’s Graduate Institute, told the Associated Press news agency.


据中国医药集团有限公司网站消息,截至5月8日,国药集团中国生物新冠疫苗已在全球70个国家和地区及国际组织批准注册上市或紧急使用,100多个国家和国际组织提出采购需求,国内外供应超过2亿剂,接种已覆盖196个国别人群,是全球使用最广泛、使用效果最好、安全性最高、受好评最多的新冠疫苗。

China's Sinopharm said at least 200 million doses of its COVID-19 vaccine have been supplied across the world and over 70 countries have already approved its use.



据《马尼拉时报》5月10日报道,菲律宾卫生部周一表示,由于国药疫苗早前已经获得世卫组织的紧急使用授权,菲律宾卫生部也决定向当地监管部门紧急申请使用国药疫苗。在此之前,菲律宾已经批准中国科兴疫苗的紧急使用。

The Department of Health (Philippines), will apply for an emergency use authorization (EUA) for the BBIPB-CorVac vaccine of Chinese drugmaker Sinopharm (China National Pharmaceutical Group Co. Ltd.) which was given an emergency use listing by the World Health Organization over the weekend. 


津巴布韦《纪事报》5月10日就世卫组织批准国药疫苗撰文。文章提到, 2月18日,在经过津巴布韦科学家的全程鉴定后,该国启动了中国国药新冠疫苗的接种工作。几个月后,世卫组织将这款疫苗列入“紧急使用清单”,将推动津巴布韦的接种数增长。

The World Health Organization’s approval of the Sinopharm Covid-19 vaccine is in line with Zimbabwean scientists’ recommendations which guided the country into rolling the lifesaving vaccination in early February using this Chinese vaccine. Experts say the WHO approval of the vaccine is likely to push up vaccination figures in Zimbabwe.




津巴布韦《新闻日报》5月10日刊登标题为《中国疫苗的成功是必然》的文章。文章指出,中国参与COVAX行动,赋予其向所有人推荐其疫苗的空间。

中国疫苗从一开始就面向中低收入的“南方国家”。这些国家被抛在后面,因为富国买走了大部分价格高昂的疫苗。中国向许多非洲国家输送了大量疫苗,例如,津巴布韦收到了50多万剂中国国药集团疫苗。

The Asian giant is in the lead in terms of being able to manufacture vaccines within its territory and make them penetrate everywhere in the world for everyone.


The ability of China to be in the Covax facility has given the country room to introduce its vaccines to everyone. China has from the start targeted the low and middle income countries which are in the global south. These countries were left behind as the global north scooped most of the pricey vaccines.


The Asian giant has made huge donations to many African countries, for example Zimbabwe received more than half a million Sinopharm vaccines from the People’s Republic of China. 


英国《金融时报》5月10日也刊登文章指出,在受新冠疫情冲击最严重的拉美地区,中国疫苗正成为接种的主力。《金融时报》分析各国提供的数据后发现,在拉美应对致命的第三波疫情之际,该地区人口最多的10个国家目前接收的1.435亿剂疫苗中,逾半数来自中国。

伦敦政治经济学院全球卫生政策助理教授Clare Wenham说:“在拉丁美洲和其他一些发展中国家,接种更多的是中国疫苗。这反映了全球卫生领域的趋势,我们看到中国作为卫生强国的主导地位正在增强。” 

As Latin America struggles against a deadly third wave of the pandemic, China has shipped more than half of the 143.5m doses of vaccines delivered to the region’s 10 most populous nations, according to a Financial Times analysis of data provided by governments. 


“There are more Chinese jabs in arms in Latin America and in some other developing nations,” said Clare Wenham, assistant professor of global health policy at the London School of Economics. “This mirrors trends in global health, where we are seeing increased Chinese dominance as a health power.”



推荐阅读:
中国国药疫苗“入世”了!
对话思想者 | 乌拉圭总统拉卡列:能得到中国疫苗的支援,是乌拉圭之幸

    您可能也对以下帖子感兴趣

    文章有问题?点此查看未经处理的缓存